790703-49-0

Basic information

• Product Name: 2-Oxazolidinone, 3-[3-fluoro-4-(phenylmethoxy)phenyl]-5-(hydroxymethyl)-, (5R)-
• CAS NO: 790703-49-0
• Molecular Formula: C17H16FNO4
• Molecular Weight: 317.317
• Mol File: 790703-49-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-Oxazolidinone, 3-[3-fluoro-4-(phenylmethoxy)phenyl]-5-(hydroxymethyl)-, (5R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Oxazolidinone, 3-[3-fluoro-4-(phenylmethoxy)phenyl]-5-(hydroxymethyl)-, (5R)-(790703-49-0)
• EPA Substance Registry System: 2-Oxazolidinone, 3-[3-fluoro-4-(phenylmethoxy)phenyl]-5-(hydroxymethyl)-, (5R)-(790703-49-0)

Safety Data

• Hazardous Substances Data: 790703-49-0(Hazardous Substances Data)

Upstream product

• 790703-40-1 (4-benzyloxy-3-fluorophenyl)carbamic acid benzyl ester 
• 60456-26-0 (R)-glycidyl butyrate 
• 100-39-0 benzyl bromide 
• 403-19-0 2-fluoro-4-nitrophenol 
• 369-34-6 3,4-difluoronitrobenzene 
• 100-51-6 benzyl alcohol 
• 168268-00-6 4-(benzyloxy)-3-fluoroaniline 
• 76243-24-8 1-(benzyloxy)-2-fluoro-4-nitrobenzene 

Downstream Products

• 926279-54-1 (5R)-3-(4-benzyloxy-3-fluoro-phenyl)-5-(isoxazol-3-yloxymethyl)-oxazolidin-2-one 
• 1025097-10-2 1-cyclopropyl-6-fluoro-7-[4-({2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl] phenoxy}methyl)-4-hydroxypiperidin-1-yl]-4-oxo-1,4-dihydroquinolin-3-carboxylic acid 
• 1025097-81-7 1-cyclopropyl-6-fluoro-7-{(RS)-3-[2-fluoro-4-((R)-5-hydroxymethyl-2-oxo-oxazolidin-3-yl)-phenoxymethyl]-3-hydroxy-pyrrolidin-1-yl}-4-oxo-1,4dihydro-quinoline-3-carboxylic acid 
• 1025097-90-8 (RS)-3-[2-fluoro-4-((R)-5-hydroxymethyl-2-oxo-oxazolidin-3-yl)-phenoxymethyl]-pyrrolidine-1-carboxylic acid benzyl ester 
• 1025098-00-3 7-(4-(bis-benzyloxy-phosphoryloxy)-4-{4-[(R)-5-(tert-butyl-dimethyl-silanyloxymethyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxymethyl}-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid benzyl ester 
• 1025097-79-3 7-(4-{4-[(R)-5-((S)-2-amino-propionyloxymethyl)-2-oxo-oxazolidin-3yl]-2-fluoro-phenoxymethyl}-4-hydroxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4oxo-1,4-dihydro-quinoline-3-carboxylic acid hydrochloride 
• 1025097-67-9 7-(4-{4-[(R)-5-((S)-2-tert-butoxycarbonylamino-propionyloxymethyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxymethyl}-4-hydroxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid benzyl ester 
• 1025097-71-5 7-(4-{4-[(R)-5-(bis-benzyloxy-phosphoryloxymethyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxymethyl}-4-hydroxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid 
• 1025098-02-5 7-{4-[4-((R)-5-acetoxymethyl-2-oxo-oxazolidin-3-yl)-2-fluoro-phenoxymethyl]-4-phosphonooxy-piperidin-1-yl}-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid benzyl ester 
• 1025097-69-1 7-(4-{4-[(R)-5-((S)-2-tert-butoxycarbonylamino-propionyloxymethyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxymethyl}-4-hydroxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid 
• 1025097-98-6 7-(4-{4-[(R)-5-(tert-butyldimethyl-silanyloxymethyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxymethyl}-4-hydroxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid benzyl ester 
• 1025097-18-0 1-cyclopropyl-6-fluoro-7-{4-[2-fluoro-4-((R)-2-oxo-5-phosphonooxymethyl-oxazolidin-3-yl)-phenoxymethyl]-4-hydroxy-piperidin-1-yl}-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid 
• 1025097-40-8 1-cyclopropyl-6-fluoro-7-{4-[2-fluoro-4-((R)-5-hydroxymethyl-2-oxo-oxazolidin-3-yl)-phenoxymethyl]-4-phosphonooxy-piperidin-1-yl}-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid 
• 1025097-65-7 1-cyclopropyl-6-fluoro-7-{4-[2-fluoro-4-((R)-5-hydroxymethyl-2-oxo-oxazolidin-3-yl)-phenoxymethyl]-4-hydroxy-piperidin-1-yl}-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid benzyl ester 

Relevant articles and documents

Synthesis, antibacterial activities, mode of action and acute toxicity studies of new oxazolidinone-fluoroquinolone hybrids

To combat bacterial resistance, a series of new oxazolidinone-fluoroquinolone hybrids have been synthesized and characterized. All synthetic hybrids were preliminarily evaluated for their in vitro antibacterial activities against 6 standard strains and 3 clinical isolates. The majority of hybrids displayed excellent activities against Gram-positive bacteria, but limited activities against Gram-negative bacteria. Hybrids OBP-4 and OBP-5 were found to be the most promising compounds. Further, in vitro antibacterial activities, mode of action and acute toxicity in mice of hybrids OBP-4 and OBP-5 were investigated. Hybrids OBP-4 and OBP-5 exhibited potent activities against Gram-positive bacteria, including drug-resistant strains. Correspondingly, studies on the mode of action of hybrids OBP-4 and OBP-5 indicated a strong inhibitory activity on protein synthesis by binding the active site of 50S subunit, but a weak inhibitory action on DNA synthesis. In addition, LD50 values of hybrids OBP-4 and OBP-5 in the acute oral toxicity were larger than 2000 mg/kg, suggesting a good safety profile.

Preparation method of Cadazolid key intermediate

The invention discloses a preparation method of a Cadazolid key intermediate. The preparation method comprises following steps: reacting a compound represented by the formula (4) with a non-nucleophilic strong base, reacting the reaction product with (R)-

INTERMEDIATE PRODUCTS FOR PRODUCING OXAZOLIDINONE-QUINOLONE HYBRIDS

The invention relates to intermediate products (ZP) for a novel and efficient synthesis of compounds, wherein the pharmacophores of quinolone and oxazolidinone are linked together by means of a chemically stable linker.